Valuation of symptomatic hepatitis A in adults: Estimates based on time trade-off and willingness-to-pay measurement

PharmacoEconomics

Volumn 20, Issue 11, 2002, Pages 739-747

  Jacobs, R J ^a   Moleski, R J ^b   Meyerhoff, A S ^a  

^a Capitol Outcomes Research Inc   (United States)

^b RJM Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONOXINOL 9;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEPATITIS A; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIFE EXPECTANCY; MALE; MEASUREMENT; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; SOCIOECONOMICS; SYMPTOMATOLOGY;

EID: 0036374882     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220110-00003     Document Type: Article

References (45)

1. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries
2. The cost effectiveness of vaccinating American children against hepatitis A
3. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates
4. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults
5. Cost effectiveness analysis of vaccination against hepatitis A in travellers
6. Cost-effectiveness of hepatitis A vaccination in healthcare workers
7. Cost effectiveness of vaccinating food service workers against hepatitis A infection
8. The economics of vaccinating food service workers against hepatitis A
9. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
10. Frequency of illness associated with epidemic hepatitis A virus infections in adults
11. The cost of hepatitis A infections in American adolescents and adults in 1997
12. Economic models of hepatitis A virus immunization
13. Estimating the cost of illness
14. The 4 consumer surpluses
15. Valuing changes in health risks: A comparison of alternative measures
16. Utility approach to measuring health-related quality of life
17. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis
18. Cost-effectiveness of 6 and 12 months of interferon therapy for chronic hepatitis C
19. Cost-effectiveness of interferon-2b treatment for hepatitis B e antigen-positive chronic hepatitis B
20. Assessment of utilities and health-related quality of life in patients with chronic liver disease
21. Atypical clinical manifestations of hepatitis A
22. The role of cost-effectiveness analysis in health and medicine
23. Outcome measurement in economic evaluation
24. Using willingness to pay to value alternative models of antenatal care
25. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection
26. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs
27. Epidemiology of hepatitis A: Seroepidemiology and risk groups in the USA
28. Hepatitis A virus infections in the United States: Model-based estimates and implications for childhood immunization
29. Prevention of hepatitis A through active or passive immunization: Recommendations of the advisory committee on immunization practices (ACIP)
30. Willingness-to-pay as a measure of benefits: Relevant questions in the context of public decisionmaking about health care programs
31. Toward consistency in cost-utility analyses: Using national measures to create condition-specific values
32. The contingent valuation method in health care
33. Measurement of the validity of utility elicitations performed by computer interview
34. Comparing three versions of the time tradeoff: Time for a change?
35. Parents' preferences for outcomes associated with childhood vaccinations
36. Aiding priority setting in health care: Is there a role for the contingent valuation method?
37. Willingness to pay for environmental goods in Norway: A contingent valuation study with real payments
38. Valuing the environment through contingent valuation